Clinical studies have shown that IMGN632 and venetoclax (a BCL-2 inhibitor for patients with acute myeloid leukemia) combined with azacitidine showed a consistent anti-leukemia synergistic effect, and the synergistic anti-leukemia effect between IMGN632 and venetoclax was verified in leukemia cell lines and xenotransplantation (PDX) derived from patients with acute myeloid leukemia. Here, BCL2 is linked to acute myeloid leukemia.